XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.97

-1.0%

2:01 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (9160)	3/12/1999 6:56:00 PM
From: Edscharp	Read Replies (2) of 17367

George, Previous to Xoma and Neuprex has there ever been a phase III trial that used similar criterion as the Neuprex trials? That is, where the protocol included a double-blinded study whose final results were contingent upon the number of deaths of patients. It occurs to me that if you had a copy of this study (or studies) you might be able to glean invaluable insights into the methodology of DSMB. How many deaths they were looking for, the number of accruals required, etc. Perhaps someone in Xomaland could be of help in this. It seems likely that when Xoma sat down to discuss protocol with DSMB that someone at Xoma may have done some research on previous protocols. Of course, if the protocol being conducted on Neuprex is unique then this posting is for naught. My thought for the day.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next